BR112021025256A2 - Interações terapêuticas de leuco metiltionínio - Google Patents
Interações terapêuticas de leuco metiltionínioInfo
- Publication number
- BR112021025256A2 BR112021025256A2 BR112021025256A BR112021025256A BR112021025256A2 BR 112021025256 A2 BR112021025256 A2 BR 112021025256A2 BR 112021025256 A BR112021025256 A BR 112021025256A BR 112021025256 A BR112021025256 A BR 112021025256A BR 112021025256 A2 BR112021025256 A2 BR 112021025256A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- treatment
- methods
- interactions
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Steroid Compounds (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1909493.7A GB201909493D0 (en) | 2019-07-01 | 2019-07-01 | Therapeutic interactions |
| PCT/EP2020/068422 WO2021001380A1 (en) | 2019-07-01 | 2020-06-30 | Therapeutic interactions of leucomethylthioninium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021025256A2 true BR112021025256A2 (pt) | 2022-01-25 |
Family
ID=67540109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021025256A BR112021025256A2 (pt) | 2019-07-01 | 2020-06-30 | Interações terapêuticas de leuco metiltionínio |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230031369A1 (enExample) |
| EP (1) | EP3989954A1 (enExample) |
| JP (1) | JP7638915B2 (enExample) |
| KR (1) | KR20220027203A (enExample) |
| CN (1) | CN114126622A (enExample) |
| AU (1) | AU2020298758B2 (enExample) |
| BR (1) | BR112021025256A2 (enExample) |
| CA (1) | CA3143790A1 (enExample) |
| GB (1) | GB201909493D0 (enExample) |
| IL (1) | IL289338B2 (enExample) |
| MX (1) | MX2021015292A (enExample) |
| WO (1) | WO2021001380A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3487505T3 (pl) | 2016-07-25 | 2023-10-09 | Wista Laboratories Ltd. | Podawanie i dawkowanie diaminofenotiazyn |
| BR112021000802A2 (pt) | 2018-07-26 | 2021-04-13 | Wista Laboratories Ltd. | Dosagem otimizada de diaminofenotiazinas em populações |
| GB202500018D0 (en) * | 2025-01-02 | 2025-02-19 | Wista Lab Ltd | Long term dosing of neurodegenerative disorders utilising methylthioninium (mt) containing compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| CN104119294B (zh) | 2006-03-29 | 2018-10-30 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物的制备方法 |
| AU2008265045B2 (en) | 2007-06-19 | 2014-02-27 | Taurx Therapeutics Management Ltd. | Phenothiazine compounds for treating Mild Cognitive Impairment |
| PT2954932T (pt) | 2007-10-03 | 2018-12-12 | Wista Lab Ltd | Utilização terapêutica de diaminofenotiazinas |
| CN101911081A (zh) | 2007-11-05 | 2010-12-08 | 维斯塔实验室有限公司 | 用于临床试验的体系 |
| KR101888713B1 (ko) | 2011-02-11 | 2018-08-14 | 위스타 레보레이토리스 리미티드 | 페노티아진 디아미늄 염 및 이의 용도 |
| PL3487505T3 (pl) | 2016-07-25 | 2023-10-09 | Wista Laboratories Ltd. | Podawanie i dawkowanie diaminofenotiazyn |
| GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| BR112021000802A2 (pt) * | 2018-07-26 | 2021-04-13 | Wista Laboratories Ltd. | Dosagem otimizada de diaminofenotiazinas em populações |
-
2019
- 2019-07-01 GB GBGB1909493.7A patent/GB201909493D0/en not_active Ceased
-
2020
- 2020-06-30 BR BR112021025256A patent/BR112021025256A2/pt unknown
- 2020-06-30 AU AU2020298758A patent/AU2020298758B2/en active Active
- 2020-06-30 MX MX2021015292A patent/MX2021015292A/es unknown
- 2020-06-30 EP EP20739286.1A patent/EP3989954A1/en active Pending
- 2020-06-30 US US17/620,949 patent/US20230031369A1/en not_active Abandoned
- 2020-06-30 WO PCT/EP2020/068422 patent/WO2021001380A1/en not_active Ceased
- 2020-06-30 KR KR1020227003213A patent/KR20220027203A/ko not_active Ceased
- 2020-06-30 CA CA3143790A patent/CA3143790A1/en active Pending
- 2020-06-30 JP JP2021577641A patent/JP7638915B2/ja active Active
- 2020-06-30 CN CN202080048557.6A patent/CN114126622A/zh active Pending
-
2021
- 2021-12-23 IL IL289338A patent/IL289338B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021001380A1 (en) | 2021-01-07 |
| US20230031369A1 (en) | 2023-02-02 |
| GB201909493D0 (en) | 2019-08-14 |
| IL289338B2 (en) | 2026-07-01 |
| AU2020298758A1 (en) | 2022-02-24 |
| CA3143790A1 (en) | 2021-01-07 |
| IL289338B1 (en) | 2026-03-01 |
| EP3989954A1 (en) | 2022-05-04 |
| JP7638915B2 (ja) | 2025-03-04 |
| IL289338A (en) | 2022-02-01 |
| JP2022538642A (ja) | 2022-09-05 |
| MX2021015292A (es) | 2022-01-18 |
| AU2020298758B2 (en) | 2026-07-30 |
| KR20220027203A (ko) | 2022-03-07 |
| CN114126622A (zh) | 2022-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022015613A (es) | Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental. | |
| BR112023013033A2 (pt) | Regimes de tratamento com dexmedetomidina | |
| BR112018068906A2 (pt) | composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo | |
| BRPI1013990A2 (pt) | método para tratar uma doença , e, combinação anticâncer | |
| BR112021018591A2 (pt) | Compostos e usos dos mesmos | |
| MY188365A (en) | Diagnosis and treatments relating to th2 inhibition | |
| MX2018007669A (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert. | |
| EP4327873A3 (en) | Tpp1 formulations and methods for treating cln2 disease | |
| Hirschfeld | Depression epidemiology and its treatment evolution | |
| BR112018074981A2 (pt) | tratamentos de câncer | |
| PH12016500715A1 (en) | Di-isopropyl-phosphinoyl-alkane (dapa) compounds as topical agents for the treatment of sensory discomfort | |
| BR112014012054A2 (pt) | métodos de tratamento com deferiprona | |
| MX2023003993A (es) | Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina. | |
| MX2019002047A (es) | Metodos y composiciones para tratar infecciones fungicas cutaneas. | |
| MX2021015292A (es) | Interacciones terapeuticas de leucometiltioninio. | |
| MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| PH12019501129A1 (en) | Therapies for the treatment of lidocaine-ineffective and hypokalemic conditions | |
| MX2018015893A (es) | Compuestos anti-cancer. | |
| MY180772A (en) | Novel therapeutic mirtazapine combinations for use in pain disorders | |
| DOP2022000095A (es) | Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con nmp con navitoclax | |
| Domènech et al. | Psicoterapias cognitivas | |
| CL2022000496A1 (es) | Métodos para el tratamiento de la enfermedad cln2 en sujetos pediátrico | |
| BR112018069195A2 (pt) | método, composição e kit para prever a responsividade de um paciente com câncer sólido a um agente anticancerígeno e método para triar agente terapêutico específico do paciente para tratamento de câncer sólido | |
| Kennedy | Difficulties in diagnostic staging of human African trypanosomiasis | |
| MX2021015947A (es) | Métodos para tratar trastornos neurodegenerativos solicitudes relacionadas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |